Effects of Celecoxib and Ly117018 on Breast Cancer Cells
Author Information
Author(s): Klaus H. Baumann, Elmar Klusmeier, Isabel Eggemann, Silke Reinartz, Achim Almeroth, Mathias Kalder, Uwe Wagner
Primary Institution: University Hospital of Gießen and Marburg
Hypothesis
The SERM Ly117018 and the COX-2 inhibitor celecoxib synergistically inhibit cell proliferation of ER-positive MCF-7 and ER-negative MDA-MB-435 human breast cancer cells in vitro.
Conclusion
The study found that the combination of celecoxib and Ly117018 has a moderate synergistic effect on inhibiting the growth of breast cancer cells.
Supporting Evidence
- Celecoxib and Ly117018 were shown to inhibit breast cancer cell proliferation when used alone.
- The combination of the two drugs revealed a moderate synergistic growth inhibitory activity.
- The study excluded drug antagonism between celecoxib and Ly117018.
Takeaway
This study shows that two drugs, celecoxib and Ly117018, can work together to help stop breast cancer cells from growing.
Methodology
The study used cell proliferation assays and western blot analysis to evaluate the effects of the drugs on breast cancer cell lines.
Limitations
The study was conducted in vitro, which may not fully represent in vivo conditions.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website